%3Aformat(webp)&w=3840&q=75)
ProstaLund
ProstaLund is active in medical technology. The company specializes in research, development and further treatment of prostate enlargement (BPH). Via the company's CoreTherm, heat treatment of benign prostatic hyperplasia is given, without the need for a surgical procedure. The vision is to offer alternative solutions to traditional approaches. The company was originally founded in 1991 and has operations on a global level, with its head office in Lund. ProstaLund has been listed on Nasdaq First North Growth market since July 2019 (ticker: PLUN).
Stock price
Company information
No Data Available
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
